Study finds people with type 2 diabetes at higher risk of death from both obesity-related and non-obesity related cancers

October 02, 2018

Being overweight or obese may put adults with diabetes at greater risk of dying from cancer than their diabetes-free counterparts, particularly for obesity-related cancers such as those arising from the bowel, kidney, and pancreas in men and women, and from the breast and endometrium (lining of the uterus) in women, according to a large observational study being presented at this year's European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany (1-5 October).

The study, involving almost 177,000 adults with type 2 diabetes and 853,000 matched controls, unexpectedly found that people with type 2 diabetes were at heightened risk of dying from non-obesity related cancers, suggesting that there might be non-obesity related mechanisms linking diabetes to cancer.

Type 2 diabetes affects more than 415 million people worldwide, and is linked with higher cancer mortality. Cancer is the second most common cause of death in people with diabetes, and in some studies is now the leading cause ahead of cardiovascular deaths. Whether this increased risk is directly related to type 2 diabetes, caused by for example longer periods of high blood glucose, or indirectly, due to common risk factors like obesity, is not known.

Obesity is known to independently increase the risk of death from several cancers (eg, breast, kidney, bowel, and womb). Whether there is a link between elevated BMI and excess risk of developing obesity-related cancers in people with type 2 diabetes is incompletely understood.

To provide more evidence, researchers from the University of Manchester in the UK analysed data on 176,886 adults (average age 60 years) with type 2 diabetes from the UK Clinical Practice Research Datalink and 852,946 matched controls without diabetes between 2008 and 2015, to compare the risk of dying from 13 obesity-related cancers and non-obesity-related cancers, and to assess the link between BMI and cancer mortality in individuals with type 2 diabetes. The BMI analysis sample group consisted of 145,769 individuals who had their BMI recorded before diabetes diagnosis. The results were adjusted for influential factors including age, smoking, ethnicity, and deprivation.

During an average 7.1 years of follow-up, 9606 deaths due to cancer occurred in people with type 2 diabetes and 37,853 in those without diabetes.

Overall, it was estimated that men with type 2 diabetes were 22% more likely to die from any cancer than men without diabetes. For women the risk was 31% higher.

Interestingly, while men and women with diabetes were considerably more likely to die from obesity-related cancers than their diabetes-free counterparts (84% and 47% higher respectively); they were also at greater risk of dying from non-obesity related cancers (6% and 18% higher respectively).

Moreover, in people with diabetes, a high BMI (35-39.9 kg/m2) was found to heighten the risk of dying for some specific obesity-related cancers. This increased risk was strongest for endometrial cancer, with obese diabetics more than four times as likely to die from the disease as their healthy weight peers.

"Our findings support the idea that obesity-related mechanisms contribute to the heightened risk of dying from cancer in people with type 2 diabetes", says co-author Ms Nasra Alam from the University of Manchester in the UK. "However, the higher risk for non-obesity related cancers also suggests that other pathways are involved. It seems likely that factors associated with obesity and diabetes contribute differentially to specific cancer types."
-end-


Diabetologia

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.